Double-whammy cancer treatment

Israel’s Kahr Medical plans to begin human trials of its DSP107 treatment on lung cancer patients. It will be tested both standalone and in combination with Roche’s Tecentriq (atezolizumab). DSP107 finds and marks cancer cells, then alerts the immune system and blocks the cancer.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *